Lantern Pharma Inc. reported financial results for the first quarter ended March 31, 2026.
“On May 15, 2026, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the first quarter ended March 31, 2026.”
Lantern Pharma Inc. — fact timeline
Source-grounded facts extracted from Lantern Pharma Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Lantern Pharma Inc. entered into Purchase Agreement with institutional investors valued at approximately $4.4 million (effective 2026-05-12).
“On May 12, 2026, Lantern Pharma Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors”
Lantern Pharma Inc. reported financial results for the fiscal year and fourth quarter ended December 31, 2025.
“On March 30, 2026, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the fiscal year and fourth quarter ended December 31, 2025.”
Lantern Pharma Inc.: Reduced quorum requirement for stockholder meetings from a majority to one-third (33.33%) of shares entitled to vote (effective 2025-07-24).
“On July 24, 2025, the Board approved an amendment to the Company’s By-laws (the “By-laws”), effective immediately. The amendment modified the provisions for determining a quorum for a meeting of stockholders of the Company and effectively reduced the quorum requirement from a majority of the shares entitled to vote at the meeting to one-third (33.33%) of the shares entitled to vote at the meeting.”
Lantern Pharma Inc. reported financial results for the first quarter 2024.
“On May 9, 2024, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the first quarter ended March 31, 2024.”
Lantern Pharma Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.
“On March 18, 2024, Lantern Pharma Inc. (the "Company") will issue a press release announcing its financial results for the fiscal year and fourth quarter ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.”
Lantern Pharma Inc. reported financial results for the third quarter ended September 30, 2023.
“On November 8, 2023, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the third quarter ended September 30, 2023.”
Lantern Pharma Inc. reported financial results for the second quarter ended June 30, 2023.
“Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the second quarter ended June 30, 2023.”
Lantern Pharma Inc. shareholders approved Ratification of the appointment of EisnerAmper LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-16 meeting.
“Ratification of Independent Registered Public Accounting Firm : In addition, our stockholders ratified the appointment of EisnerAmper LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023, with shares voted as follows: For 7,015,460 Against 41,115 Abstain 5,164 There were no broker non-votes on the ratification of our independent registered public accounting firm.”
Lantern Pharma Inc. shareholders approved Approval of an amendment to the Second Amended and Restated Lantern Pharma Inc. 2018 Equity Incentive Plan to increase the number of shares available for issuance by an additional 250,000 shares at the 2023-06-16 meeting.
“Amendment to Equity Incentive Plan : Our stockholders approved an amendment to the Equity Incentive Plan to increase the number of shares of the Company’s common stock available for issuance under the Equity Incentive Plan by an additional 250,000 shares, with shares voted as follows: For 4,145,520 Against 96,840 Abstain 14,138 Broker Non-Votes 2,805,241”
Lantern Pharma Inc. shareholders approved Election of six directors to serve until the 2024 Annual Meeting of Stockholders at the 2023-06-16 meeting.
“Election of Directors : All of the persons nominated to serve on our board of directors, namely Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Maria Maccecchini, Franklyn Prendergast, and David S. Silberstein, were elected to our board of directors, with shares voted as follows: Name For Withheld Broker Non-Vote Donald Jeff Keyser 3,812,521 443,977 2,805,241 Panna Sharma 4,064,225 192,273 2,805,241 Vijay Chandru 3,810,172 446,326 2,805,241 Maria Maccecchini 3,811,686 444,812 2,805,241 Franklyn Prendergast 4,048,745 207,753 2,805,241 David S. Silberstein 4,060,996 195,502 2,805,241”
Lantern Pharma Inc. reported financial results for first quarter ended March 31, 2023.
“will issue a press release announcing its financial results for the first quarter ended March 31, 2023.”
Lantern Pharma Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2022.
“On March 20, 2023, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the fiscal year and fourth quarter ended December 31 , 2022.”
Lantern Pharma Inc. reported financial results for third quarter ended September 30, 2022.
“Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the third quarter ended September 30 , 2022.”
Leslie W. Kreis, Jr. departed as Director at Lantern Pharma Inc..
“On April 20, 2022, Leslie W. Kreis, Jr. notified Lantern Pharma Inc. (the “Company”) that he will not stand for reelection to the Company’s Board of Directors.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.